The objective of the present study was to assess the expression of CD105 and its association with overall survival in three subtypes of
renal cell carcinoma (RCC), namely clear cell (cc)RCC, papillary (p)RCC and chromophobe (ch)RCC. Data regarding the transcriptome and copy number of genes in RCC
tumor samples and survival were obtained from The
Cancer Genome Atlas. Bioinformatics analysis revealed that CD105 is overexpressed in ccRCC
tumor tissue vs. normal renal tissue, and a higher CD105 copy number in ccRCC tissues was significantly associated with longer patient survival. The effect of the
mRNA expression of CD105 in all three types of RCC and the copy number in pRCC and chRCC on patient survival was insignificant, but certain trends were observed. In addition, CD105
mRNA expression was associated with the
metastasis and
tumor stage, as well as pathological stage in ccRCC and pRCC. Pathway enrichment analysis revealed that CD105 may, through translation initiation of associated genes, promote RCC progression. The results of the present study suggest that in RCC
tumors, the association of CD105 with different stages is complex. To evaluate the role of CD105 in RCC, its function should be assessed in addition to its expression. The exact influence of CD105
mRNA expression and copy number in RCC
tumors on patient survival and the underlying mechanisms require further elucidation.